KALA BIO, Inc. (NASDAQ:KALA) Sees Large Increase in Short Interest

KALA BIO, Inc. (NASDAQ:KALA) was the target of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 37,500 shares, an increase of 28.0% from the October 15th total of 29,300 shares. Based on an average daily trading volume, of 17,600 shares, the days-to-cover ratio is currently 2.1 days. Approximately 1.0% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $15.00 target price on shares of KALA BIO in a research note on Monday, August 19th.

KALA BIO Price Performance

Shares of KALA BIO stock traded up $0.08 during trading on Friday, hitting $6.84. The company’s stock had a trading volume of 6,684 shares, compared to its average volume of 83,789. KALA BIO has a 52 week low of $4.21 and a 52 week high of $10.97. The company has a debt-to-equity ratio of 3.18, a quick ratio of 3.07 and a current ratio of 2.15. The stock has a 50-day moving average price of $6.00 and a two-hundred day moving average price of $6.29.

KALA BIO (NASDAQ:KALA) last issued its earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.43) by $0.50. Equities analysts anticipate that KALA BIO will post -11.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP purchased a new stake in shares of KALA BIO, Inc. (NASDAQ:KALA) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO makes up approximately 1.0% of SR One Capital Management LP’s holdings, making the stock its 9th biggest holding. SR One Capital Management LP owned about 15.76% of KALA BIO at the end of the most recent quarter. 24.61% of the stock is owned by institutional investors.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.